hormone replacement therapy (HRT)

It was determined that the overall health risks of the area far outweighed the benefits of the hormone-replacement therapy, and though all-cause mortality was unaffected by the say, HRT was deemed inconsistent with "the requirements for a viable intervention for primary coil ginmill of chronic diseases" (CHD) (Risks and benefits, 2002).

Hlatky, Boothroyd and Vittinghoff (2002) had as well been looking at the set up of HRT in postmenopausal women, following women with coronary arteria disease in outpatient and community settings in clinical centers crossways the United States to determine if the therapy improved health-related quality of living in these patients in the Heart and Estrogen/Progestin Replacement think (HERS) trial. The subjects were randomly assigned to a treatment (1380 patients) or retain chemical conclave (1383 patients), the treated group receiving 0.625 mg of conjugated estrogen of equine origin and 2.5 mg of medroxyprogesterone acetate, the same HRT used in the Women's Health Initiative study. The control group received placebo, and all were followed for up to three years. Questionnaires were used to prize bodily function, energy/fatigue, mental health and depressive symptoms.

Over the three-year period, physical function and energy/fatigue scores declined in both groups, but the declines were more rapid in the HRT group of patients. However, the HRT group had more improve

Bauer (2002) describe on a Nurses' Health Study prospective, survey-based study of whether postmenopausal HRT could reduce the risk of recurrent CHD and tack that short-term therapy seemed to actually increase the risk, but longer-term (two years or more) therapy decreased the risk. The study has followed 122,000 female nurses since 1976, and 2,500 were included in the reported HRT study. Short-term HRT users had a 25 percent bestride higher risk of CHD compared to those who never used HRT for non-fatal myocardial infarction or fatal coronary disease.

Long-term users had a 62 percent lower risk for these two events. The study suggested that HRT should not be used solely for the prevention of recurrent CHD.

The women in this study had a mean age of 67 years, and all had hound dog, so the results of the study may not generalize to all groups of postmenopausal women, i.e. younger women, and women with no CAD (Hlatky, Boothroyd, Vittinghoff, Sharp and Whooley, 2002). These results are of particular relevance to nurses working with aged women and educating them about the risks of HRT. Nurse practitioners who can prescribe HRT should also take note of such results since they affect quality of life issues and are consistent with past studies which have shown that HRT helps depressive symptoms in older, postmenopausal women. In addition, it should be noted that older women had importantly better emotional health than younger women, which has also been entrap in other studies. However, these positive effects need to be weighed against the negative physical effects of the HRT on these patients.

ment in their depressive symptoms than control
Order your essay at Orderessay and get a 100% original and high-quality custom paper within the required time frame.